SGPL1

Across TCGA pan-cancer cohorts, SGPL1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of SGPL1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SGPL1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SGPL1 is over-expressed in tumor, although a few such as KICH and KIRC show the opposite, repressed pattern.

BLCA, LUAD, and LUSC are the cancer types where SGPL1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SGPL1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+1.334	<.001	11	view →
LUAD	Male	II,III,IV	+1.403	<.001	9	view →
LUSC	Female	All	+1.275	<.001	9	view →
STAD	Male	II,III,IV	+1.207	<.001	9	view →
LIHC	All	III,IV	+0.810	<.001	9	view →
HNSC	All	All	+0.546	<.001	9	view →
BRCA	All	III,IV	+0.927	<.001	6	view →
UCEC	All	All	+0.849	<.001	6	view →
CHOL	Male	All	+1.981	<.001	5	view →
KICH	All	All	−0.740	<.001	5	view →
PRAD	All	All	+0.400	<.001	2	view →
KIRC	Male	II,III,IV	−0.362	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

SGPL1–BLCA

Open the BLCA breakdown →